Immediately avoid or short Capricor Therapeutics (CAPR) due to severe regulatory scrutiny and devastating FDA briefing documents regarding data manipulation. Capitalize on the recent semiconductor sell-off by aggressively buying NVIDIA (NVDA) on market weakness as a long-term growth play targeting its path toward a $10 trillion valuation. Look for value-buying opportunities in Micron Technology (MU) during sharp market pullbacks to capitalize on fundamentally constrained memory supply chains. Exercise extreme caution with speculative quantum computing stocks like D-Wave (QBTS), IonQ (IONQ), and Rigetti (RGTI), considering short positions on overhyped rallies driven by empty press releases. Add Tyra Biosciences (TYRA) to your watchlist ahead of crucial clinical trial data catalysts scheduled for the first and second halves of the year.

Capricor Therapeutics (CAPR)

• The company's drug trial and FDA briefing book revealed severe issues, including data manipulation, omissions, and protocol deviations.
• The speaker described the company's actions as a scheme to defraud, noting that the drug was created using minced cadaver hearts with no standard cell-type matching or autoimmune protocols.
• The stock plummeted heavily (falling 50% initially and down roughly 70% during the session) after the FDA released critical documents, and the speaker labeled the management and company as fraudulent.

Takeaways

• Avoid investing in Capricor Therapeutics as regulatory scrutiny and data integrity issues severely threaten the company's survival and drug approval prospects.

NVIDIA (NVDA)

• NVIDIA experienced a steep decline during a broader semiconductor sell-off, but the speaker remains highly bullish on the company long-term.
• The speaker highlights NVIDIA's involvement in a massive $250 billion OpenAI infrastructure facility as a major positive catalyst.
• The speaker predicts that NVIDIA will eventually become the world's first $10 trillion company.

Takeaways

• Consider buying NVIDIA on market weakness as a long-term growth play, viewing temporary dips as accumulation opportunities driven by its dominance in the AI infrastructure space.

Micron Technology (MU)

• Micron suffered a severe nosedive alongside other memory and semiconductor stocks during a market-wide "chip armageddon" sell-off.
• The speaker noted that despite heavy volatility, massive trading volume, and short-term panic, supply chains across the memory sector remain overwhelmed.
• The speaker views the heavy sell-off in memory stocks as an instinctive buying opportunity rather than a permanent structural failure.

Takeaways

• Look for value-buying opportunities in Micron during sharp market pullbacks, keeping a close eye on memory cycle dynamics and supply constraints.

Intel (INTC)

• Intel experienced significant downward pressure and free fall during the session's broader tech sell-off, struggling to recover past highs.
• The speaker noted that the stock appears heavily oversold following recent sessions, though market sentiment remains weak.

Takeaways

• Exercise caution with Intel given its persistent weakness, but monitor the stock as an oversold turnaround candidate if broader semiconductor sentiment stabilizes.

Quantum and AI Penny Stocks (D-Wave, IonQ, Rigetti)

• Quantum computing stocks like D-Wave (QBTS), IonQ (IONQ), and Rigetti (RGTI) experienced unjustified double-digit rallies based on "nothing burger" press releases and minor partnerships (such as D-Wave with AT&T).
• The speaker dismissed these companies as cash-burning scams with high share dilution, poor gross margins, and nonexistent earnings.

Takeaways

• Consider shorting overhyped quantum computing stocks that rally on speculative PR announcements disconnected from fundamental business realities.

Tyra Biosciences (TYRA)

• The biotech company has a pipeline centered around targeted kinase inhibitors, specifically highlighting its FGFR inhibitor drug candidate dabogratinib (targeting non-muscle invasive bladder cancer and other conditions).
• The company maintains a healthy cash position with little-to-no debt, and key institutional investors like RA Capital hold substantial stakes.
• Clinical trial data catalysts are expected in the first and second halves of the year.

Takeaways

• Add Tyra Biosciences to your watchlist to track upcoming clinical trial data readouts, but perform thorough due diligence on competitive drug toxicity profiles before investing.

Kioxia Holdings

• Analyzed alongside SanDisk as a major player in the Flash memory market, Kioxia trades at an exceptionally low valuation multiple (noted as roughly 4x earnings) despite a heavy debt load resulting from past Toshiba restructuring.
• The speaker noted that the Flash memory supply chain is heavily constrained and difficult to keep up with.

Takeaways

• Research Kioxia as a deep-value play within the memory sector if you want exposure to constrained Flash memory supply chains at low earnings multiples.